Moleculin Biotech, Inc. (MBRX) Dividend History

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing oncology drugs and treatments for difficult-to-treat cancers. The company specializes in the research and development of small molecule therapeutics targeting cancer metabolism, tumor microenvironment, and resistant cancer cells. Moleculin's pipeline includes compounds designed for oral administration, aiming to address unmet medical needs in oncology.

5300 Memorial Drive, Houston, TX, 77007
Phone: 713-300-5160
Website: https://www.moleculin.com

Dividend History

Moleculin Biotech, Inc. currently does not pay dividends

Company News

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin reported positive results from a Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. The trial showed improved overall survival and progression-free survival, with a clinical benefit rate of 59.4%.

GlobeNewswire Inc.
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin Biotech, a late-stage pharmaceutical company, presented its top five reasons for why investors should pay attention to the company in 2025, including updates on its lead drug candidate Annamycin and other pipeline programs.

Benzinga
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Biotech, Inc. announced that its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium. The abstract focuses on the company's drug candidate Annamycin, which is in development for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Benzinga
Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Biotech, a late-stage pharmaceutical company, announced that its CEO Walter Klemp participated in a Virtual Investor segment to discuss the progress of the company's Phase 3 pivotal trial evaluating Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) patients.

Benzinga
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Biotech announced progress in the development of its drug candidate Annamycin for the treatment of acute myeloid leukemia (AML), including positive Phase 2 data and an upcoming pivotal Phase 3 trial.

Benzinga

Dividend data last updated 06/07/2025 10:51:16 UTC